DK2849798T3 - Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder - Google Patents

Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder Download PDF

Info

Publication number
DK2849798T3
DK2849798T3 DK13791618.5T DK13791618T DK2849798T3 DK 2849798 T3 DK2849798 T3 DK 2849798T3 DK 13791618 T DK13791618 T DK 13791618T DK 2849798 T3 DK2849798 T3 DK 2849798T3
Authority
DK
Denmark
Prior art keywords
chelat
oligonucleotid
procedures
complex
polypeptide compositions
Prior art date
Application number
DK13791618.5T
Other languages
Danish (da)
English (en)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2849798(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Application granted granted Critical
Publication of DK2849798T3 publication Critical patent/DK2849798T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2292Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
DK13791618.5T 2012-05-18 2013-05-17 Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder DK2849798T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
DK2849798T3 true DK2849798T3 (da) 2021-05-31

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13791618.5T DK2849798T3 (da) 2012-05-18 2013-05-17 Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder

Country Status (34)

Country Link
US (1) US9492506B2 (https=)
EP (1) EP2849798B1 (https=)
JP (1) JP2015517504A (https=)
KR (1) KR102068109B1 (https=)
CN (1) CN104349793B (https=)
AU (1) AU2013262416B2 (https=)
BR (1) BR112014028654A2 (https=)
CA (1) CA2873529C (https=)
CL (1) CL2014003134A1 (https=)
CO (1) CO7131387A2 (https=)
CR (1) CR20140527A (https=)
CY (1) CY1124345T1 (https=)
DK (1) DK2849798T3 (https=)
DO (1) DOP2014000264A (https=)
EA (1) EA035967B1 (https=)
EC (1) ECSP14027694A (https=)
ES (1) ES2873844T3 (https=)
HR (1) HRP20210840T1 (https=)
HU (1) HUE054875T2 (https=)
IL (1) IL235548B (https=)
LT (1) LT2849798T (https=)
MX (1) MX346239B (https=)
MY (1) MY168778A (https=)
NZ (1) NZ703095A (https=)
PH (1) PH12014502551B1 (https=)
PL (1) PL2849798T3 (https=)
PT (1) PT2849798T (https=)
RS (1) RS62030B1 (https=)
SG (1) SG11201407599SA (https=)
SI (1) SI2849798T1 (https=)
SM (1) SMT202100319T1 (https=)
TW (1) TWI635864B (https=)
WO (1) WO2013170386A1 (https=)
ZA (1) ZA201408674B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723672C (en) 2007-05-11 2019-09-03 Adynxx, Inc. Gene expression and pain
EP3511022A1 (en) 2012-05-10 2019-07-17 Adynxx, Inc. Formulations for the delivery of active ingredients
AU2013308045B2 (en) * 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections
HRP20231400T1 (hr) 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
PE20211783A1 (es) * 2018-11-08 2021-09-08 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルb型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
EP2330194A3 (en) * 2002-09-13 2011-10-12 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
JP2006519235A (ja) * 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
CA2543696A1 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
WO2006042418A1 (en) * 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
EP1928498A4 (en) * 2005-09-29 2009-11-11 Cell Biosciences Inc S METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
EP1942911A4 (en) * 2005-09-29 2009-08-19 Replicor Inc THERAPEUTIC MOLECULES AND USES THEREOF
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
AU2008334948B2 (en) * 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
KR101704988B1 (ko) * 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
KR20120095397A (ko) * 2009-10-16 2012-08-28 글락소 그룹 리미티드 Hbv 안티센스 억제제
BR112013003875B1 (pt) * 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
AU2013308045B2 (en) 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections

Also Published As

Publication number Publication date
CA2873529C (en) 2020-08-18
IL235548A0 (en) 2015-01-29
HUE054875T2 (hu) 2021-10-28
US20130309201A1 (en) 2013-11-21
PT2849798T (pt) 2021-05-18
JP2015517504A (ja) 2015-06-22
WO2013170386A1 (en) 2013-11-21
MX2014014021A (es) 2015-02-10
KR102068109B1 (ko) 2020-01-21
TWI635864B (zh) 2018-09-21
PH12014502551A1 (en) 2015-01-21
EP2849798A1 (en) 2015-03-25
EP2849798A4 (en) 2016-03-09
AU2013262416A1 (en) 2014-12-18
BR112014028654A2 (pt) 2017-10-10
CA2873529A1 (en) 2013-11-21
CR20140527A (es) 2014-12-15
CY1124345T1 (el) 2022-07-22
EA201401278A1 (ru) 2015-04-30
ECSP14027694A (es) 2015-12-31
HK1204279A1 (en) 2015-11-13
KR20150013309A (ko) 2015-02-04
CN104349793B (zh) 2017-11-10
NZ703095A (en) 2016-07-29
TW201408308A (zh) 2014-03-01
PL2849798T3 (pl) 2021-10-18
IL235548B (en) 2019-07-31
ES2873844T3 (es) 2021-11-04
CL2014003134A1 (es) 2015-02-13
EP2849798B1 (en) 2021-04-07
MY168778A (en) 2018-12-04
LT2849798T (lt) 2021-08-10
CN104349793A (zh) 2015-02-11
RS62030B1 (sr) 2021-07-30
DOP2014000264A (es) 2015-01-31
EA035967B1 (ru) 2020-09-07
HRP20210840T1 (hr) 2021-08-06
SG11201407599SA (en) 2014-12-30
MX346239B (es) 2017-03-13
US9492506B2 (en) 2016-11-15
ZA201408674B (en) 2016-01-27
SMT202100319T1 (it) 2021-09-14
CO7131387A2 (es) 2014-12-01
AU2013262416B2 (en) 2017-05-11
PH12014502551B1 (en) 2019-10-11
SI2849798T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
IL269045A (en) Aptamers and uses thereof
BR112015003227A2 (pt) processos de clicoconjugação e composições
DK2920167T3 (da) Hydrazinyl-indol-forbindelser og konjugater
DK2850202T3 (da) Fremgangsmåder og grupper
LT3725778T (lt) Enzalutamido kompozicijos
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2906684T3 (da) T-celle-modificerende forbindelser og anvendelser deraf
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
FR2997014B1 (fr) Composition sterile dermo-injectable
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
DK2911506T3 (da) Driftreducerende sammensætninger
BR112014032798A2 (pt) composição
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
EP2911305A4 (en) MULTIPLEXER
BR112015001562A2 (pt) biotinas e composições
ME03413B (me) Kompozicije које sadrže peg i askorbat
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
EP2842163A4 (en) NONLINEAR MEMRISTORS
DK3326642T3 (da) Langtidsvirkende koagulationsfaktorer og brugen deraf
EP2735260A4 (en) Endoscope
DK2849798T3 (da) Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder
HRP20190123T1 (hr) Postupak pročišćavanja saponina